Axon Enterprise INC Stock
Price
Target price
€368.30
€368.30
-2.350%
-8.8
-2.350%
-
20.02.26 / Tradegate
WKN: A2DPZU / Symbol: TASR / Name: Axon / Stock / Aerospace & Defense / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Axon Enterprise INC Stock
We can see a decrease in the price for Axon Enterprise INC. Compared to yesterday it has lost -€8.800 (-2.350%).
So far the community has only identified positive things for Axon Enterprise INC stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Axon Enterprise INC in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Axon Enterprise INC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Axon Enterprise INC | -2.350% | 1.797% | -30.457% | -28.624% | -25.142% | 106.123% | 152.001% |
| Moog Inc. | 1.250% | 7.096% | 20.000% | 71.128% | 38.113% | 208.211% | 340.301% |
| Heico Corp. | 0.170% | 6.533% | 1.462% | 38.985% | 6.457% | 80.848% | 179.820% |
| HEICO Corp | 0.920% | 4.762% | -5.172% | 30.178% | 1.852% | 69.231% | 129.024% |
Comments
News
AppLovin Shares Crash Despite Stellar Growth. Is It Time to Buy the Stock on the Dip?
Despite posting strong fourth-quarter growth and issuing upbeat guidance, shares of AppLovin (NASDAQ: APP) were crashing after the company reported its results. The stock has now lost more than 40%
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported
Why Axon Enterprise Stock Plunged Week
Shares of Axon Enterprise (NASDAQ: AXON), the maker of TASER electrical weapons and body cameras, were taking a dive this week, even though there was no major company-specific news out on it.